EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma

Yinhua Tan, Chunxiu Xiao, Zhifan Wang, Yuhang Kong, Yamei Huang, Zhichang Liu, Qiang Wu, Chenyu Wu, Manyu Zhao, Jingyao Chen, Kai Xiao iD

Pharmaceuticals · 25.12.2025 · 19 (1) · 47

DOI: 10.3390/ph19010047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 25.12.2025. Verfasst von Yinhua Tan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Precision Therapeutics, Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidi…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by the National Natural Science Foundation of China, the Frontier Medical Center, Tianfu Jincheng Laboratory Foundation, the Sichuan Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) remains a major challenge in the treatment of EGFR-mutant lung adenocarcinoma (LUAD). This study aimed to develop and characterize representative models of acquired EGFR-TKI resistance and to identify potential therapeutic targets mediating this process.

Methods

Resistant models of PC9 and LUAD-PDCs were generated using a standardized dose-escalation protocol. The resulting models were characterized by drug response assays, morphology, and transcriptomic sequencing. Candidate target genes were validated across all resistant models using siRNA knockdown followed by re-sensitization assays. Clinical relevance was further examined through analysis of publicly available datasets.

Results

These generated models displayed stable resistant phenotypes and unique transcriptomic alterations. Cross-model analysis revealed MUC16 as a consistently upregulated gene associated with resistance. Functional validation demonstrated that MUC16 depletion re-sensitized all resistant models to EGFR-TKIs. Furthermore, analysis of clinical data linked high MUC16 expression to poorer patient outcomes.

Conclusions

This study establishes stable in vitro models for investigating acquired resistance in EGFR-mutant LUAD and identifies MUC16 as a functionally validated and clinically relevant mediator of EGFR-TKI resistance, providing a potential therapeutic target for overcoming drug resistance.

Schlagwörter

Stichwörter der Autor:innen

EGFR-TKIsMUC16drug resistancelung adenocarcinomatranscriptomics

Autor:innen und Institutionen

  • Laboratory of Precision Therapeutics, Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Frontiers Science Center for Disease-Related Molecular Network, We…
  • Frontier Medical Center, Tianfu Jincheng Laboratory, Chengdu 610041, China.

ORCID-Profile: Kai Xiao

Förderung

  • This study was supported by the National Natural Science Foundation of China
  • the Frontier Medical Center, Tianfu Jincheng Laboratory Foundation
  • the Sichuan Science and Technology Program
  • the Fundamental Research Funds for the Central Universities
  • the Chengdu Science and Technology Program
  • he 1·3·5 project of State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University
  • 1·3·5 project for Clinical New Technology, West China Hospital, Sichuan University
  • the Institutional Research Fund from Sichuan University

Zitieren

APA

Tan, Y., Xiao, C., Wang, Z., Kong, Y., Huang, Y., Liu, Z., Wu, Q., Wu, C., Zhao, M., Chen, J., & Xiao, K. (2025). Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma. Pharmaceuticals, 19(1), 47. https://doi.org/10.3390/ph19010047

Vancouver

Tan Y, Xiao C, Wang Z, Kong Y, Huang Y, Liu Z, et al. Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma. Pharmaceuticals. 2025;19(1):47. doi:10.3390/ph19010047

BibTeX
@article{Tan2025,
  author = {Tan, Yinhua and Xiao, Chunxiu and Wang, Zhifan and Kong, Yuhang and Huang, Yamei and Liu, Zhichang and Wu, Qiang and Wu, Chenyu and Zhao, Manyu and Chen, Jingyao and Xiao, Kai},
  title = {Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {19},
  number = {1},
  pages = {47},
  doi = {10.3390/ph19010047}
}
Kostenlos starten →